肺がん生物学 MOC

肺がん固有の driver 変異機序、lung-specific 病態、肺がん細胞の分子・細胞生物学に関する研究を統合する。

ドメイン定義

含む: EGFR / ALK / ROS1 / KRAS-G12C / KRAS-G12D / HER2 / MET / BRAF / RET / NTRK / NRG1 driver の分子機構、acquired resistance 機序 (on-target 変異 / bypass pathway / lineage plasticity の三層)、肺がん特異的 TME (tumor microenvironment、PD-L1 expression、neoantigen 動態、SPP1+ TAM や ZNF683+CD8 T 細胞などの免疫応答決定因子)、ADC (antibody-drug conjugate) 応答を規定する標的内在化・DDR (DNA damage response)・SLFN11 などの分子軸、SCLC (small cell lung cancer) neuroendocrine 分化、肺がん幹細胞・high-plasticity cell state (HPCS)、NSCLC (non-small cell lung cancer) subtypes (adenocarcinoma / squamous / large cell) の分子分類。

含まない: 治療効果の臨床研究 (→ lung-cancer-treatment)、がん種非依存の横断的バイオロジー (→ cancer-biology)、脳転移・骨転移などの転移先固有の機序 (→ 各転移 MOC)。

Basic-Oncogene and genetics の中でも肺がん以外の臓器がん研究 (乳がん BRCA など) は本 MOC から除外し、cancer-biology に分類する。

現状の合意 (State of the Field)

肺腺がんは driver oncogene 別に明確な分子サブクラスへ階層化される疾患であり、EGFR (東アジア腺がん 30–50%)、KRAS (欧米 25–30%、うち G12C 約 13%)、ALK 融合 (3–7%)、ROS1 (1–2%)、MET ex14 skipping、HER2 ex20 insertion、BRAF V600E、RET / NTRK / NRG1 融合がそれぞれ異なる receptor tyrosine kinase / RAS-MAPK (RAS–mitogen-activated protein kinase) 軸の構成的活性化を駆動する。KRAS-G12C 特異的 covalent inhibitor のパラダイム (janes et al. Cell 2018) は、長らく “undruggable” とされた switch-II ポケットを GDP-bound state でトラップし sotorasib / adagrasib の臨床実装に直結した。近年は non-cysteine 変異にも阻害が及び、non-covalent KRAS G12D 阻害薬 MRTX1133 が前臨床マウス LUAD (lung adenocarcinoma、肺腺がん) で抗腫瘍効果を示し (Chan et al. Nature 2026)、臨床では tri-complex 機構で活性型 RAS を直接トラップする次世代 G12D 阻害薬 RMC-9805 が NSCLC 評価可能 18 例で ORR (objective response rate、奏効率) 61% (95% CI 36–83%)・DCR (disease control rate) 89% を報告するなど (Luo et al. Med 2026)、長らく undruggable とされた G12D を含む pan-KRAS / GDP-state trap の臨床展開が加速している。

Acquired resistance のパラダイムは三層構造で整理される：(1) on-target gatekeeper / solvent-front 変異 (EGFR T790M、osimertinib 後 C797S、ALK G1202R、ROS1 G2032R)、(2) bypass pathway 活性化 (MET 増幅、HER2 増幅、KRAS / BRAF 二次変異、RAS-MAPK 再活性化)、(3) lineage plasticity (SCLC transformation、扁平上皮 transition、EMT [epithelial-mesenchymal transition、上皮間葉転換])。一次治療 osimertinib 耐性時の最新 ctDNA (circulating tumor DNA、循環腫瘍 DNA) landscape では C797S 約 6% (FLAURA 血漿 ctDNA、n=557)、MET 増幅 15% 以上、RTK 融合 (ALK / RET / BRAF / FGFR) 3–5%、SCLC 転換 3–10% と整理されるが、約 50% は既知単一遺伝子異常で説明できない。EGFR-TKI 耐性後に新規検出される融合では ALK 42.9%・RET 35.7% が高頻度で、これらは EGFR 非依存の bypass driver として後続治療標的になる (Zhao et al. NatRevClinOncol 2026)。single-cell 解析は residual disease 内に複数の耐性プログラムが non-genetic に共存し TKI 圧で順次選択されることを示し (Maynard et al. Cell 2020、Kashima et al. CancerRes 2021)、その細胞起源として high-plasticity cell state (HPCS) が同定されていた (Marjanovic et al. CancerCell 2020)。2026 年には Slc4a11-MCD レポーターで HPCS が in vivo に可視化され (腫瘍細胞の 17.0 ± 4.3%)、lineage tracing で全腫瘍細胞状態への双方向 transition hub であることが実証された。耐性腫瘍では HPCS 由来 fraction が 17.0% から 45.3% へ増加し (約 3.8 倍)、HPCS 先制除去 (DT ablation / anti-DTR CAR-T [chimeric antigen receptor T cell、キメラ抗原受容体 T 細胞]) が化学療法・KRAS G12D 阻害薬への耐性出現を強力に抑制 (耐性出現までの中央値 7.2→21.6 週、Cox HR 0.32) し、anti-DTR CAR-T は OS (overall survival、全生存期間) を有意に延長した (中央値 95 vs 35 日、HR 0.21)。HPCS は可塑性と耐性 reservoir の双方向ハブとして因果的に位置づけられ、再生上皮・乳がん・大腸がんにも保存された普遍プログラムとして同定された (Chan et al. Nature 2026)。

Co-mutation landscape は driver の臨床表現型を強く修飾する。KRAS-mutant 腺がんは TP53 共変異 (KP)、STK11/LKB1 共変異 (KL)、CDKN2A/B + low-TTF1 (KC) の三亜型に分かれ、KL 群は TMB (tumor mutational burden、腫瘍変異負荷) 高値・PD-L1 陽性でも PD-1 阻害に primary resistance を示す (ORR 7.4% vs KP 35.7%、PFS [progression-free survival、無増悪生存期間] HR [hazard ratio、ハザード比] 1.87) (Skoulidis et al. CancerDiscov 2018)。KEAP1 loss は KRAS 駆動腺がんを NRF2 依存に glutamine 代謝へ rewire し glutaminase 阻害で標的化可能とされ (Romero et al. NatMed 2017)、これら co-mutation 軸は IO (immuno-oncology、免疫療法) / RT (radiotherapy、放射線療法) / 代謝標的の層別化基準として実装が進む。

Lineage plasticity による耐性は分子機構の解像度が大きく上がった。EGFR-TKI 後の SCLC transformation は RB1 機能喪失を必要条件とするが (Niederst et al. NatCommun 2015)、神経内分泌形質転換は変異よりも転写リプログラミング (PRC2 / PI3K-AKT / WNT 活性化、Notch 抑制、3p 欠失 85%) が主体で、EGFR-PDX で samotolisib + osimertinib 併用が腫瘍増殖を追加で 55.8% 抑制し転換を遅延させた (Quintanal-Villalonga et al. CancerDiscov 2021)。組織転換は系統特異的で、Myc は神経内分泌系譜・EGFR は AT2 (alveolar type 2、肺胞 II 型上皮) 系譜の driver として機能し、Akt 活性化と basal-like stem 中間状態が LUAD→SCLC 転換を媒介する (Gardner et al. Science 2024)。KRAS G12C/LKB1 変異腺がんでは adagrasib 圧下で ELF5-DNp63 軸を介した腺→扁平上皮転換 (AST) が KRAS 非依存の耐性状態を生み、AST 可塑性 signature / KRT6A が反応不良の予測因子となる (Tong et al. CancerCell 2024)。

SCLC では ASCL1 / NEUROD1 / POU2F3 / YAP1 (NAPY) の四亜型分類が神経内分泌系譜可塑性の基盤となり、MYC 増幅が NEUROD1-high variant を駆動する。亜型は治療脆弱性を規定し、免疫炎症型 SCLC-I が IO 上乗せ効果と、SCLC-N が CDK / Aurora kinase 阻害感受性と関連する。各亜型は SUV39H1-DNMT3A/B 軸を介したメチル化パターンの差 (SCLC-P 低メチル化・SCLC-N 高メチル化) を持ち、DNA メチル化分類器 (SCLC-DMC / cfDMC) が組織 95.8%・血漿 cfDNA (cell-free DNA、無細胞 DNA) 100% (43/43) の精度で subtype を non-invasive に判定する。化学免疫療法の選択圧下で SCLC-A→SCLC-I への subtype switching を液体生検で縦断追跡でき、subtype 動態モニタリングが現実的になった (Heeke et al. CancerCell 2024)。

ADC (antibody-drug conjugate、抗体薬物複合体) 応答機序・DDR (DNA damage response、DNA 損傷応答)・TME が新しい predictive 軸として前景化している。既治療進行 NSCLC 100 例の ICARUS-LUNG01 第 II 相 (Dato-DXd ORR 26.0%、非扁平上皮で 30.5%) の translational 解析では、SLFN11 高発現・TROP2 cytoplasmic 分布の均一性 (内在化効率) ・治療誘導性免疫活性化 (IFN [interferon、インターフェロン] α) が奏効に関連し、RAD51 を含む DNA 修復経路の早期活性化が抵抗性に寄与した (SLFN11 CRISPR KO で感受性 10–50 倍低下) (Planchard et al. CancerCell 2026)。これは ADC payload (Topo-I) が引き起こす single-strand break → replication fork collapse → SLFN11 依存的 apoptosis という機序を示し、PARP / ATR / WEE1 阻害剤との rational combination の根拠となる。EGFR-TKI 耐性後の治療は MET 標的 (savolitinib + osimertinib、SACHI 試験の 3 世代既治療サブグループで PFS 6.9 vs 3.0 か月、HR 0.32) や TROP2 / HER3 ADC・bispecific へと多軸化し、upfront 併用 (FLAURA2 で PFS HR 0.62・OS HR 0.77、MARIPOSA で PFS HR 0.70) が耐性出現の遅延戦略として確立しつつある (Zhao et al. NatRevClinOncol 2026)。TME 側では ZNF683+CD8+ T 細胞が IO 奏効の予測因子であり、これを起点に構築された 19 遺伝子 ZNFRS (ZNF683-related signature) が TMB と独立な予後・免疫抑制指標として 10 コホートで検証され、高スコア群を規定する SPP1 経路 (SPP1+ TAM 由来) が “cold TME” の治療標的として同定された (anti-SPP1 + anti-PD-1 併用で相乗) (Zhang et al. npjPrecisOncol 2026)。

主要エンティティ

遺伝子 (20 — Phase B Top 20 拡張)

NSCLC drivers (12):

EGFR — Activating mutation, T790M / C797S 耐性, MET amp bypass
ALK — EML4-ALK fusion variants, 世代別 TKI 耐性 (G1202R, compound mutation)
KRAS — G12C cryptic pocket, co-mutation landscape (KP/KL/KC)
ROS1 — fusion driver, ALK kinase 77% 同一, G2032R 耐性
HER2 — exon 20 ins, amplification, T-DXd ADC 標的
MET — exon 14 skipping, EGFR-TKI bypass amp
BRAF — V600E (class I), non-V600 (class II/III) の treatment 戦略
RET — fusion driver, selective RET-TKI で transformation
NTRK — NTRK1/2/3 fusion (rare in NSCLC, tissue-agnostic paradigm)
FGFR1 — squamous NSCLC 約20% amplification, druggability 議論的
NRG1 — NRG1 fusion (約0.2%), HER3/HER4 ligand, HER3-DXd 標的
ERBB3 — HER3, kinase-dead dimerization partner, HER3-DXd target

Tumor suppressor / co-mutation 修飾子 (7):

TP53 — 65–80% mutation, driver-modifying (KP subtype 主体)
RB1 — SCLC 90%+ LOF, NSCLC SCLC transformation の必要条件
STK11 — KRAS+STK11 (KL) で IO 一次抵抗性、AMPK pathway
KEAP1 — NRF2-glutamine 軸、IO/RT/化療抵抗性
CDKN2A — p16/p14ARF locus, squamous NSCLC 60%+ LOF, KC subtype
MDM2 — p53 negative regulator, TP53-WT cancers の治療標的
SPP1 — immunosuppressive TAM/neutrophil marker, TME modulator

SCLC subtype master regulator (4):

ASCL1 — SCLC-A subtype (約70%), DLL3 induction → Tarlatamab target
NEUROD1 — SCLC-N subtype (約10–20%), MYC 連動, Aurora kinase 感受性
POU2F3 — SCLC-P subtype (約10%), tuft cell origin, 化療抵抗性
MYC — SCLC variant subtype driver, c-MYC/MYCN/MYCL 拡張

Biomarker (1):

PD-L1 — IO predictive biomarker, IFN-γ inducible, 9p24.1 amp

薬剤クラス (治療応答性研究の基盤、6)

EGFR-TKI — Acquired resistance 機序研究の基盤
ALK-TKI — Compound mutation / fusion variant 別感受性
ROS1-TKI — Solvent-front G2032R 機序
RET-inhibitor — Selective vs multi-kinase RET TKI 比較
KRAS-G12C-inhibitor — covalent trap dynamic mechanism
NTRK-inhibitor — tissue-agnostic paradigm

試験

(基礎研究中心のため少数想定。translational rationale を裏付けた試験のみ追加)

主要概念

EGFR-T790M-resistance — 1st/2nd-gen EGFR-TKI 耐性 paradigm
EGFR-C797S-resistance — 3rd-gen Osimertinib 後耐性、cis/trans allele paradigm
ALK-G1202R-compound-mutations — solvent-front mutation, Lorlatinib compound mutation
KRAS-co-mutation-landscape — KP/KL/KC 三亜型、STK11/KEAP1 IO 抵抗性
Lineage-plasticity — RB1+TP53 dual loss → SCLC transformation、HPCS hub
EMT — driver mutation context での mesenchymal shift、TKI 抵抗性
Cancer-dormancy — drug-tolerant persister cells、residual disease の生物学
SCLC-molecular-subtypes — ASCL1 / NEUROD1 / POU2F3 / YAP1 (NAPY) 四亜型、precision SCLC の基盤

(Phase D 拡張候補: MET amp bypass / EGFR exon 20 insertion / KRAS G12C resistance / NRG1 fusion biology)

Open Questions

HPCS / 可塑性ハブの先制標的化: Slc4a11+ HPCS の維持機構 (NKX2.1-HMGA2 switch、Wnt / Notch / YAP) の解明と、ヒト HPCS surface marker の同定、anti-DTR / anti-Slc4a11 CAR-T のヒト固形腫瘍への翻訳、KRAS 阻害薬・化学療法との併用による耐性 reservoir の先制除去
KRAS G12D / G12V / pan-KRAS の臨床実装: tri-complex RMC-9805 等の効果持続と耐性機序 (AST など lineage 系も含む)、GDP-state / 活性型 RAS trap を non-cysteine 変異全般へ拡張する戦略、LKB1 共変異下での反応不良の克服
EGFR osimertinib 後の未知耐性 (約 50%): 既知単一遺伝子異常で説明できない耐性の分子基盤、ctDNA-MRD (minimal residual disease、微小残存病変) ガイドの adaptive 治療介入と upfront 併用 (FLAURA2 / MARIPOSA) による出現遅延 — ただし併用が生む新たな未知耐性表現型の解明
ADC 感受性・抵抗性バイオマーカーの統合: SLFN11 / TROP2 内在化 (cytoplasmic 均一性) / DDR (RAD51) を組み合わせた複合 predictive marker の前向き検証、ADC + PARP/ATR/WEE1 または IO の rational combination、扁平上皮で低い奏効の機序
NE (neuroendocrine、神経内分泌) / 扁平上皮転換の予測と先制介入: RB1/TP53 dual loss・AST 可塑性 signature (KRT6A)・cfDNA methylation subtype 動態による転換の早期検出と、PI3K-AKT / ELF5-DNp63 軸の先制遮断 (BET 阻害薬等との併用)
cold TME (SPP1 / KL) の免疫感作: STK11/KEAP1 共変異・SPP1+ TAM が駆動する非炎症性 TME を IO 応答性へ転換する併用戦略 (anti-SPP1、glutaminase 阻害、metabolic vulnerability) と、ZNF683 / ZNFRS を前向き層別化に実装する検証

重要論文 Top 10

★★★★★ janes et al. Cell 2018 — KRAS-G12C covalent 阻害の概念実証、Sotorasib/Adagrasib の起点
★★★★★ Skoulidis et al. CancerDiscov 2018 — KRAS 三亜型分類 (KP/KL/KC) と STK11 共変異 IO 抵抗性
★★★★★ Romero et al. NatMed 2017 — KEAP1/NRF2 loss → glutamine 依存性、glutaminase 標的化
★★★★ Maynard et al. Cell 2020 — TKI 治療下 residual disease の non-genetic 耐性 scRNA-seq
★★★★ Marjanovic et al. CancerCell 2020 — HPCS state — lineage transformation hub の同定
★★★★★ Mok et al. NEnglJMed 2009 — IPASS: EGFR mutation を predictive biomarker として確立
★★★★ Kashima et al. CancerRes 2021 — scRNA-seq EGFR-TKI 耐性 heterogeneity
★★★★ Marine et al. NatRevCancer 2020 — Non-genetic resistance paradigm 統合 review
★★★★ Quintanal-Villalonga et al. CancerDiscov 2021 — Neuroendocrine transformation pathway の multiomics 解析
★★★★ Niederst et al. NatCommun 2015 — RB1 LOF → EGFR-TKI 後 SCLC transformation の機序確立

最新追加論文 Top 10

Jong et al. JImmunotherCancer 2026 — Basic-Others
Wang et al. Carcinogenesis 2026 — Basic-Others
Xu et al. CancerCell 2026 — Basic-Others
Goto et al. Nature 2024 — Basic-Others
Li et al. CancerImmunolRes 2026 — Basic-Others
Shukla et al. NatBiotechnol 2015 — Basic-Others
Weickhardt et al. JThoracOncol 2012 — Basic-Others
Nik-Zainal et al. Cell 2012 — Basic-Others
Repetto et al. ClinCancerRes 2026 — Basic-Others
Gu et al. CancerRes 2026 — Basic-Oncogene and genetics

全論文リスト (カテゴリ別、自動生成)

Basic-Oncogene and genetics

Bandlamudi et al. CancerCell 2026 — Cancer type-specific variation in patterns of driver alterations across 50,000 tumors
Liao et al. CancerCell 2026 — Targeting TROP2 in drug-tolerant persister cells delays EGFR tyrosine kinase inhibitor resistance in non-small-cell
Sill et al. CancerCell 2026 — Advancing CNS tumor diagnostics with expanded DNA methylation-based classification
Scaparone et al. CancerDiscov 2026 — EML4-ALK mediates resistance to KRAS G12C inhibition and induces an
Wei et al. CancerDiscov 2026 — Abrogation of oncogenic RAS signaling
Sarkar et al. CancerGeneTher 2026 — TP53 mutation at codon 179 metabolically reprograms cancer cells to promote invasion
Gu et al. CancerRes 2026 — EGFR N-glycosylation catalyzed by NDST2 promotes lenvatinib resistance in hepatocellular carcinoma
Maurais et al. Cell 2026 — Genome instability triggers intercellular DNA transfer between human cells
Wong et al. Cell 2026 — A recipe for chaos extrachromosomal DNA and the hallmarks of cancer
Yap et al. Cell 2026 — Targeting genomic instability in cancer
Yang et al. CellRep 2026 — Pan-cancer evolution signatures link clonal expansion to dynamic changes in the tumor immune microenvironment
Liu et al. FrontImmunol 2026 — Pan-cancer analysis of OSR2 with a focus on underlying mechanisms and therapeutic implications in lung adenocarcinoma
Pineda et al. ModPathol 2026 — A comprehensive mutational and histopathological analysis of STK11-mutant non-small cell lung carcinomas
Klink et al. NatCommun 2026 — Targeted degradation of USP7 in solid cancer cells reveals distinct effects of deubiquitinase degraders and inhibitors
Li et al. NatCommun 2026 — Molecular glue that stabilizes the LRPPRC-MET-G4 interaction complex to drive MET downregulation
Cheek et al. NatGenet 2026 — Age distinguishes selection from causation in cancer genomes
Chan et al. Nature 2026 — Critical role for a high-plasticity cell state in lung cancer
Franca et al. Nature 2026 — A mechanism for adaptive genome regulation in cancer
Hessey et al. Nature 2026 — Evolutionary characterization of lung cancer metastasis
Lopez-Bigas et al. Nature 2026 — Tumour promotion through the lens of evolution
Pich et al. Nature 2026 — Somatic evolution following cancer treatment in normal tissue
Sankar et al. Nature 2026 — Genetic elements promote retention of extrachromosomal DNA in cancer cells
Zhang et al. Science 2026 — Stem cell control in the lung by an autocrine injury-activated igf complex
Wang et al. SignalTransductTargetTher 2026 — Disrupting SOX2 self-association and condensate formation to overcome chemotherapeutic drug resistance in lung squamous
Attardi et al. TrendsCancer 2026 — P53 defender of lineage fidelity and foe of plasticity in cancer and regeneration
Tan et al. TrendsCancer 2026 — Targeting cyclin-dependent kinases in cancer emerging therapeutics and clinical strategies
Sui et al. CellDeathDiscov 2025 — Lactylation in cancer metabolic mechanism and therapeutic strategies
Pich et al. NEnglJMed 2025 — Tumor-infiltrating clonal hematopoiesis
You et al. Cell 2024 — Disruption of cellular plasticity by repeat RNAs in human pancreatic cancer
AlKhafaji et al. NatBiotechnol 2024 — High-throughput RNA isoform sequencing using programmed cDNA concatenation
Gardner et al. Science 2024 — Lineage-specific intolerance to oncogenic drivers restricts histological transformation
Lengel et al. CancerCell 2023 — Genomic mapping of metastatic organotropism in lung adenocarcinoma
Ning et al. CancerChemotherPharmacol 2023 — The role of alternative splicing in lung cancer
Stein et al. CancerDiscov 2023 — LKB1-dependent regulation of TPI1 creates a divergent metabolic liability between human and mouse lung adenocarcinoma
Chaudhary et al. CancerResCommun 2023 — Activation of KrasG12D in subset of alveolar type II cells enhances cellular plasticity in lung adenocarcinoma
Xu et al. CellDeathDis 2023 — SRSF3AMOTL1 splicing axis promotes the tumorigenesis of nasopharyngeal carcinoma through regulating the nucleus
Keun et al. MolCell 2023 — RBM39 A druggable metabolic sensor linking RNA splicing, transcriptional regulation, and metabolic reprogramming in
Ma et al. MolCell 2023 — SRSF2 plays an unexpected role as reader of m5c on mRNA, linking epitranscriptomics to cancer
Li et al. Nature 2023 — Non-cell-autonomous cancer progression from chromosomal instability
Girish et al. Science 2023 — Oncogene-like addiction to aneuploidy in human cancers
Concepcion et al. CancerDiscov 2022 — Smarca4 inactivation promotes lineage-specific transformation and early metastatic features in the lung
Johnson et al. CancerDiscov 2022 — Classification of KRAS-activating mutations and the implications for therapeutic intervention
Myer et al. CancerDiscov 2022 — The genomics of colorectal cancer in populations with African and European ancestry
Yi et al. CancerDiscov 2022 — Live-cell imaging shows uneven segregation of extrachromosomal DNA elements and transcriptionally active
Hareendran et al. CancerLett 2022 — Carboxypeptidase E and its splice variants Key regulators of growth and metastasis in multiple cancer types
Cui et al. Cancers 2022 — Dynamic expression of epcam in primary and metastatic lung cancer is controlled by both genetic and epigenetic
Nguyen et al. Cell 2022 — Genomic characterization of metastatic patterns from prospective clinical sequencing of 25,000 patients
he et al. Cell 2022 — A human fetal lung cell atlas uncovers proximal-distal gradients of differentiation and key regulators of epithelial
Reggiardo et al. CellRep 2022 — Mutant KRAS regulates transposable element RNA and innate immunity via KRAB zinc-finger genes
Wong-Rolle et al. JImmunotherCancer 2022 — Spatial meta-transcriptomics reveal associations of intratumor bacteria burden with lung cancer cells showing a
Peng et al. MolTher 2022 — Impacts and mechanisms of alternative mRNA splicing in cancer metabolism, immune response, and therapeutics
vanLeen et al. NatGenet 2022 — The genomic and spatial mobility of extrachromosomal DNA and its implications for cancer therapy
Doman et al. NatProtoc 2022 — Designing and executing prime editing experiments in mammalian cells
Yi et al. NatRevGenet 2022 — Extrachromosomal DNA amplifications in cancer
Fennell et al. Nature 2022 — Non-genetic determinants of malignant clonal fitness at single-cell resolution
Funnell et al. Nature 2022 — Single-cell genomic variation induced by mutational processes in cancer
Yang et al. ProteinCell 2022 — Emerging roles of spliceosome in cancer and immunity
Liu et al. SciTranslMed 2022 — A germline SNP in BRMS1 predisposes patients with lung adenocarcinoma to metastasis and can be ameliorated by targeting
Altemose et al. Science 2022 — Complete genomic and epigenetic maps of human centromeres
Church et al. Science 2022 — A next-generation human genome sequence
Wu et al. SignalTransductTargetTher 2022 — Multi-omics analysis reveals RNA splicing alterations and their biological and clinical implications in lung
Noer et al. TrendsGenet 2022 — Extrachromosomal circular DNA in cancer History, current knowledge, and methods
McGrail et al. AnnOncol 2021 — High tumor mutation burden fails to predict immune checkpoint blockade response across all cancer types
Wang et al. BMCPulmMed 2021 — The pattern of alternative splicing in lung adenocarcinoma shows novel events correlated with tumorigenesis and immune
Ghosh et al. CancerCell 2021 — Mutant p53 suppresses innate immune signaling to promote tumorigenesis
Leader et al. CancerCell 2021 — Single-cell analysis of human non-small cell lung cancer lesions refines tumor classification and patient stratification
Sanclemente et al. CancerCell 2021 — RAF1 kinase activity is dispensable for KRASp53 mutant lung tumor progression
Quintanal-Villalonga et al. CancerDiscov 2021 — Multiomic analysis of lung tumors defines pathways activated in neuroendocrine transformation
Saito et al. CancerSci 2021 — Multiple mutations within individual oncogenes
Hahn et al. Cell 2021 — An expanded universe of cancer targets
Satpathy et al. Cell 2021 — A proteogenomic portrait of lung squamous cell carcinoma
Singh et al. ClinCancerRes 2021 — NRF2 activation promotes aggressive lung cancer and associates with poor clinical outcomes
Sitthideatphaiboon et al. ClinCancerRes 2021 — STK11LKB1 mutations in NSCLC are associated with KEAP1NRF2-dependent radiotherapy resistance targetable by glutaminase
Li et al. JThoracOncol 2021 — Potential unreliability of uncommon ALK, ROS1, and RET genomic breakpoints in predicting the efficacy of targeted
Mikubo et al. JThoracOncol 2021 — Mechanism of drug tolerant persister cancer cells the landscape and clinical implication for therapy
Tang et al. JThoracOncol 2021 — Timing and origins of local and distant metastases in lung cancer
Argelaguet et al. NatBiotechnol 2021 — Computational principles and challenges in single-cell data integration
Prensner et al. NatBiotechnol 2021 — Noncanonical open reading frames encode functional proteins essential for cancer cell survival
Lehtio et al. NatCancer 2021 — Proteogenomics of non-small cell lung cancer reveals molecular subtypes associated with specific therapeutic targets
Avsec et al. NatGenet 2021 — Base-resolution models of transcription-factor binding reveal soft motif syntax
Hargreaves et al. NatGenet 2021 — Chromatin openness requires continuous SWISNF activity
Rosswog et al. NatGenet 2021 — Chromothripsis followed by circular recombination drives oncogene amplification in human cancer
Black et al. NatRevCancer 2021 — Genetic and non-genetic clonal diversity in cancer evolution
Bugter et al. NatRevCancer 2021 — Mutations and mechanisms of WNT pathway tumour suppressor in cancer
Ghiraldini et al. NatRevCancer 2021 — Solid tumours hijack the histone variant network
Goodall et al. NatRevCancer 2021 — RNA in cancer
Kakiuchi et al. NatRevCancer 2021 — Clonal expansion in non-cancer tissues
Nam et al. NatRevGenet 2021 — Integrating genetic and non-genetic determinants of cancer evolution by single-cell multi-omics
Hung et al. Nature 2021 — ecDNA hubs drive cooperative intermolecular oncogene expression
Sroka et al. Nature 2021 — An epigenetic fulcrum tipped in cancer
Vassiliadis et al. Nature 2021 — Mutation alters chromatin changes during injury response to drive cancer
Yuan et al. Nature 2021 — Elevated NSD3 histone methylation activity drives squamous cell lung cancer
Yum et al. Nature 2021 — Tracing oncogene-driven remodelling of the intestinal stem cell niche
Payne et al. Science 2021 — In situ genome sequencing resolves DNA sequence and structure in intact biological samples
Quinn et al. Science 2021 — Single-cell lineages reveal the rates, routes, and drivers of metastasis in cancer xenografts
Zhang et al. SignalTransductTargetTher 2021 — Alternative splicing and cancer a systematic review
Nesta et al. TrendsGenet 2021 — Hotspots of human mutation
Bailey et al. AnnOncol 2020 — Extrachromosomal DNA-relieving heredity constraints, accelerating tumour evolution
Ireland et al. CancerCell 2020 — MYC drives temporal evolution of small cell lung cancer subtypes by reprogramming neuroendocrine fate
LaFave et al. CancerCell 2020 — Epigenomic state transitions characterize tumor progression in mouse lung adenocarcinoma
Lim et al. CancerCell 2020 — Advancing cancer research and medicine with single-cell genomics
Marjanovic et al. CancerCell 2020 — Emergence of a high-plasticity cell state during lung cancer evolution
Salvador-Barbero et al. CancerCell 2020 — CDK46 inhibitors impair recovery from cytotoxic chemotherapy in pancreatic adenocarcinoma
Binkley et al. CancerDiscov 2020 — KEAP1NFE2L2 mutations predict lung cancer radiation resistance that can be targeted by glutaminase inhibition
Gillette et al. Cell 2020 — Proteogenomic characterization reveals therapeutic vulnerabilities in lung adenocarcinoma
Kumar et al. Cell 2020 — Passenger mutations in more than 2,500 cancer genomes overall molecular functional impact and consequences
Xu et al. Cell 2020 — Integrative proteomic characterization of human lung adenocarcinoma
Dost et al. CellStemCell 2020 — Organoids model transcriptional hallmarks of oncogenic KRAS activation in lung epithelial progenitor cells
Adachi et al. ClinCancerRes 2020 — Epithelial-to-mesenchymal transition is a cause of both intrinsic and acquired resistance to KRAS G12C inhibitor in
Schoenfeld et al. ClinCancerRes 2020 — The genomic landscape of SMARCA4 alterations and associations with outcomes in patients with lung cancer
Sakamoto et al. GenomeRes 2020 — Long-read sequencing for non-small-cell lung cancer genomes
Flaherty et al. JClinOncol 2020 — Molecular landscape and actionable alterations in a genomically guided cancer clinical trial national cancer institute
Akdemir et al. NatGenet 2020 — Disruption of chromatin folding domains by somatic genomic rearrangements in human cancer
Akdemir et al. NatGenet 2020 — Somatic mutation distributions in cancer genomes vary with three-dimensional chromatin structure
Balmain et al. NatGenet 2020 — The critical roles of somatic mutations and environmental tumor-promoting agents in cancer risk
Cortes et al. NatGenet 2020 — Ciriano-Comprehensive analysis of chromothripsis in 2,658 human cancers using whole-genome sequencing
Dietlein et al. NatGenet 2020 — Identification of cancer driver genes based on nucleotide context
Kim et al. NatGenet 2020 — Extrachromosomal DNA is associated with oncogene amplification and poor outcome across multiple cancers
Mina et al. NatGenet 2020 — Discovering functional evolutionary dependencies in human cancers
Yuan et al. NatGenet 2020 — Comprehensive molecular characterization of mitochondrial genomes in human cancers
Zapatka et al. NatGenet 2020 — The landscape of viral associations in human cancers
Milanez-Almeida et al. NatMed 2020 — Cancer prognosis with shallow tumor RNA sequencing
Hausser et al. NatRevCancer 2020 — Tumour heterogeneity and the evolutionary trade-offs of cancer
Marine et al. NatRevCancer 2020 — Non-genetic mechanisms of therapeutic resistance in cancer
Bonnal et al. NatRevClinOncol 2020 — Roles and mechanisms of alternative splicing in cancer-implications for care
Mittal et al. NatRevClinOncol 2020 — The SWISNF complex in cancer-biology, biomarkers and therapy
Alexandrov et al. Nature 2020 — The repertoire of mutational signatures in human cancer
ICGCTCGA et al. Nature 2020 — Pan-cancer analysis of whole genomes
Jayavelu et al. Nature 2020 — Splicing factor YBX1 mediates persistence of JAK2-mutated neoplasms
PCAWG et al. Nature 2020 — Genomic basis for RNA alterations in cancer
Watkins et al. Nature 2020 — Pervasive chromosomal instability and karyotype order in tumour evolution
Benisty et al. ProcNatlAcadSciUSA 2020 — Mutation bias within oncogene families is related to proliferation-specific codon usage
Mayrhofer et al. ProcNatlAcadSciUSA 2020 — Mutation-oriented profiling of autoinhibitory kinase conformations predicts RAF inhibitor efficacies
Anusewicz et al. SciRep 2020 — Lung squamous cell carcinoma and lung adenocarcinoma differential gene expression regulation through pathways of notch,
Kucab et al. Cell 2019 — A compendium of mutational signatures of environmental agents
Morton et al. Cell 2019 — Functional enhancers shape extrachromosomal oncogene amplifications
Donehower et al. CellRep 2019 — Integrated analysis of TP53 gene and pathway alterations in the cancer genome atlas
LaCanna et al. JClinInvest 2019 — YapTaz regulate alveolar regeneration and resolution of lung inflammation
Murphy et al. JThoracOncol 2019 — Using genomics to differentiate multiple primaries from metastatic lung cancer
Jang et al. NatGenet 2019 — Transposable elements drive widespread expression of oncogenes in human cancers
Reiter et al. NatRevCancer 2019 — An analysis of genetic heterogeneity in untreated cancers
Verhaak et al. NatRevCancer 2019 — Extrachromosomal oncogene amplification in tumour pathogenesis and evolution
Marchal et al. NatRevMolCellBiol 2019 — Control of DNA replication timing in the 3D genome
Michalak et al. NatRevMolCellBiol 2019 — The roles of DNA, RNA and histone methylation in ageing and cancer
Treiber et al. NatRevMolCellBiol 2019 — Regulation of microRNA biogenesis and its crosstalk with other cellular pathways
Anzalone et al. Nature 2019 — Search-and-replace genome editing without double-strand breaks or donor DNA
Behan et al. Nature 2019 — Prioritization of cancer therapeutic targets using CRISPR-Cas9 screens
Wu et al. Nature 2019 — Circular ecDNA promotes accessible chromatin and high oncogene expression
Miranda et al. ProcNatlAcadSciUSA 2019 — Cancer stemness, intratumoral heterogeneity, and immune response across cancers
Augert et al. SciSignal 2019 — Targeting NOTCH activation in small cell lung cancer through LSD1 inhibition
Kahles et al. CancerCell 2018 — Comprehensive analysis of alternative splicing across tumors from 8,705 patients
Li et al. CancerCell 2018 — Loss of the FAT1 Tumor Suppressor Promotes Resistance to CDK4 6 Inhibitors via the Hippo Pathway
Razavi et al. CancerCell 2018 — The genomic landscape of endocrine-resistant advanced breast cancers
RojoDeLaVega et al. CancerCell 2018 — NRF2 and the hallmarks of cancer
Wang et al. CancerDiscov 2018 — A secondary mutation in BRAF confers resistance to RAF inhibition in a BRAFV600E-mutant brain tumor
Huang et al. Cell 2018 — Pathogenic germline variants in 10,389 adult cancers
Sanchez-Vega et al. Cell 2018 — Oncogenic signaling pathways in the cancer genome atlas
Wang et al. Cell 2018 — An acquired vulnerability of drug-resistant melanoma with therapeutic potential
Zhang et al. Cell 2018 — Targeting CDK9 reactivates epigenetically silenced genes in Cancer
janes et al. Cell 2018 — Targeting KRAS mutant cancers with a covalent G12C-specific inhibitor
Seiler et al. CellRep 2018 — Somatic mutational landscape of splicing factor genes and their functional consequences across 33 cancer types
Smith et al. CellRep 2018 — A human adult stem cell signature marks aggressive variants across epithelial cancers
Frank et al. ClinCancerRes 2018 — Clinical and pathological characteristics of KEAP1-and NFE2L2-mutated non-small cell lung carcinoma (NSCLC)
Huang et al. GenesDev 2018 — POU2F3 is a master regulator of a tuft cell-like variant of small cell lung cancer
Houle et al. GenomeRes 2018 — Aberrant PRDM9 expression impacts the pan-cancer genomic landscape
Honda et al. JCOPrecisOncol 2018 — Deleterious pulmonary surfactant system gene mutations in lung adenocarcinomas associated with usual interstitial
Du et al. MolCancer 2018 — Mechanisms of receptor tyrosine kinase activation in cancer
Grzeskowiak et al. NatCommun 2018 — In vivo screening identifies GATAD2B as a metastasis driver in KRAS-driven lung cancer
Su et al. NatCommun 2018 — SHQ1 regulation of RNA splicing is required for T-lymphoblastic leukemia cell survival
Wagner et al. NatCommun 2018 — Recurrent WNT pathway alterations are frequent in relapsed SCLC
Wang et al. NatCommun 2018 — Whole-genome sequencing reveals genomic signatures associated with the inflammatory microenvironments in chinese NSCLC
deCarvalho et al. NatGenet 2018 — Discordant inheritance of chromosomal and extrachromosomal DNA elements contributes to dynamic disease evolution in
Deribe et al. NatMed 2018 — Mutations in the SWI-SNF coplex induce a targetable dependence on oxidative phosphorylation in lung cancer
Dagogo-Jack et al. NatRevClinOncol 2018 — Tumour heterogeneity and resistance to cancer therapies
Bakhoum et al. Nature 2018 — Chromosomal instability drives metastasis through a cytosolic DNA response
Roerink et al. Nature 2018 — Intra-tumour diversification in colorectal cancer at the single-cell level
Park et al. Science 2018 — Reprogramming normal human epithelial tissues to a common, lethal neuroendocrine cancer lineage
Reiter et al. Science 2018 — Minimal functional driver gene heterogeneity among untreated metastases
Duruisseaux et al. SemCancerBiol 2018 — Lung cancer epigenetics from knowledge to applications
Mollaoglu et al. CancerCell 2017 — MYC drives progression of small cell lung cancer to a variant neuroendocrine subtype with vulnerability to aurora
Zhang et al. CancerCell 2017 — A pan-cancer proteogenomic atlas of PI3K-AKT-mTOR pathway alterations
Udyavar et al. CancerRes 2017 — Novel hybrid phenotype revealed in small cell lung cancer by a transcription factor network model that can explain
Imielinski et al. Cell 2017 — Insertions and deletions target lineage-defining genes in human cancers
McGranahan et al. Cell 2017 — Clonal heterogeneity and tumor evolution past, present, and the future
Chalmers et al. GenomeMed 2017 — Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden
Fuse et al. MolCancerTher 2017 — Mechanisms of resistance to NTRK inhibitors and therapeutic strategies in NTRK1-rearranged cancers
Jamal-Hanjani et al. NEnglJMed 2017 — Tracking the evolution of non-small-cell lung cancer
Vannini et al. NatCommun 2017 — Transcribed ultraconserved region 339 promotes carcinogenesis by modulating tumor suppressor microRNAs
Okimoto et al. NatGenet 2017 — Inactivation of Capicua drives cancer metastasis
Mardis et al. NatProtoc 2017 — DNA sequencing technologies 2006-2016
Rotow et al. NatRevCancer 2017 — Understanding and targeting resistance mechanisms in NSCLC
Schwartz et al. NatRevGenet 2017 — The evolution of tumour phylogenetics principles and practice
Neri et al. Nature 2017 — Intragenic DNA methylation prevents spurious transcription initiation
Shendure et al. Nature 2017 — DNA sequencing at 40 past, present and future
Tanay et al. Nature 2017 — Scaling single-cell genomics from phenomenology to mechanism
Turner et al. Nature 2017 — Extrachromosomal oncogene amplification drives tumour evolution and genetic heterogeneity
Yao et al. Nature 2017 — Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS
Dawson et al. Science 2017 — The cancer epigenome Concepts, challenges, and therapeutic opportunities
Campbell et al. NatGenet 2016 — Distinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas
Williams et al. NatGenet 2016 — Identification of neutral tumor evolution across cancer types
Andor et al. NatMed 2016 — Pan-cancer analysis of the extent and consequences of intratumor heterogeneity
Gawad et al. NatRevGenet 2016 — Single-cell genome sequencing current state of the science
McFadden et al. ProcNatlAcadSciUSA 2016 — Mutational landscape of EGFR-, MYC-, and kras-driven genetically engineered mouse models of lung adenocarcinoma
Heuckmann et al. AnnOncol 2015 — A new generation of cancer genome diagnostics for routine clinical use overcoming the roadblocks to personalized cancer
Saito et al. CancerRes 2015 — Development of lung adenocarcinomas with exclusive dependence on oncogene fusions
Schott et al. CancerRes 2015 — Genome medicine in cancer what’s in a name
Pefanis et al. Cell 2015 — RNA exosome-regulated long non-coding RNA transcription controls super-enhancer activity
Matsuda et al. HumMolGenet 2015 — Genome-wide association study identified SNP on 15q24 associated with bladder cancer risk in japanese population
Lopez-Chavez et al. JClinOncol 2015 — Molecular profiling and targeted therapy for advanced thoracic malignancies a biomarker-derived, multiarm,
Meric-Bernstam et al. JClinOncol 2015 — Feasibility of large-scale genomic testing to facilitate enrollment onto genomically matched clinical trials
Fraser et al. MicrobiolMolBiolRev 2015 — An overview of genome organization and how we got there from FISH to hi-C
DeNicola et al. NatGenet 2015 — NRF2 regulates serine biosynthesis in non-small cell lung cancer
Bhang et al. NatMed 2015 — Studying clonal dynamics in response to cancer therapy using high-complexity barcoding
Friedman et al. NatRevCancer 2015 — Precision medicine for cancer with next-generation functional diagnostics
Henn et al. NatRevGenet 2015 — Estimating the mutation load in human genomes
Cao et al. SciRep 2015 — Genome-wide association study on platinum-induced hepatotoxicity in non-small cell lung cancer patients
McGranahan et al. SciTranslMed 2015 — Clonal status of actionable driver events and the timing of mutational processes in cancer evolution
Serizawa et al. Cancer 2014 — Assessment of mutational profile of japanese lung adenocarcinoma patients by multitarget assays a prospective,
McFadden et al. Cell 2014 — Genetic and clonal dissection of murine small cell lung carcinoma progression by genome sequencing
Stintzing et al. ClinCancerRes 2014 — Molecular pathways turning proteasomal protein degradation into a unique treatment approach
Stransky et al. NatCommun 2014 — The landscape of kinase fusions in cancer
Helleday et al. NatRevGenet 2014 — Mechanisms underlying mutational signatures in human cancers
Cancer et al. Nature 2014 — Comprehensive molecular profiling of lung adenocarcinoma
Lawrence et al. Nature 2014 — Discovery and saturation analysis of cancer genes across 21 tumour types
Cummings et al. Oncotarget 2014 — Mer590, a novel monoclonal antibody targeting MER receptor tyrosine kinase, decreases colony formation and increases
Crystal et al. Science 2014 — Patient-derived models of acquired resistance can identify effective drug combinations for cancer
Nathanson et al. Science 2014 — Targeted therapy resistance mediated by dynamic regulation of extrachromosomal mutant EGFR DNA
deBruin et al. Science 2014 — Spatial and temporal diversity in genomic instability processes defines lung cancer evolution
Berge et al. SeminOncol 2014 — Targeted therapies in non-small cell lung cancer emerging oncogene targets following the success of epidermal growth
Koboldt et al. Cell 2013 — The next-generation sequencing revolution and its impact on genomics
Li et al. JClinOncol 2013 — Genotyping and genomic profiling of non-small-cell lung cancer implications for current and future therapies
Oxnard et al. JClinOncol 2013 — New targetable oncogenes in non-small-cell lung cancer
Cibulskis et al. NatBiotechnol 2013 — Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples
Weinstein et al. NatGenet 2013 — The cancer genome atlas pan-cancer analysis project
Mwenifumbo et al. NatRevGenet 2013 — Cancer genome-sequencing study design
Watson et al. NatRevGenet 2013 — Emerging patterns of somatic mutations in cancer
Lawrence et al. Nature 2013 — Mutational heterogeneity in cancer and the search for new cancer-associated genes
Mitsuishi et al. CancerCell 2012 — Nrf2 redirects glucose and glutamine into anabolic pathways in metabolic reprogramming
Rizzo et al. CancerPrevRes(Phila) 2012 — Key principles and clinical applications of next-generation DNA sequencing
Dawson et al. Cell 2012 — Cancer epigenetics From mechanism to therapy
Govindan et al. Cell 2012 — Genomic landscape of non-small cell lung cancer in smokers and never-smokers
Huang et al. Cell 2012 — MED12 controls the response to multiple cancer drugs through regulation of TGF-beta receptor signaling
Imielinski et al. Cell 2012 — Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing
Nik-Zainal et al. Cell 2012 — The life history of 21 breast cancers
Hoelder et al. MolOncol 2012 — Discovery of small molecule cancer drugs successes, challenges and opportunities
Gerlinger et al. NEnglJMed 2012 — Intratumor heterogeneity and branched evolution revealed by multiregion sequencing
Carter et al. NatBiotechnol 2012 — Absolute quantification of somatic DNA alterations in human cancer
Peifer et al. NatGenet 2012 — Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer
Pao et al. NatMed 2012 — Chipping away at the lung cancer genome
Collisson et al. NatRevClinOncol 2012 — What are we learning from the cancer genome
Yates et al. NatRevGenet 2012 — Evolution of the cancer genome
Nature 2012 — An integrated map of genetic variation from 1092 human genomes
TCGA et al. Nature 2012 — Comprehensive genomic characterization of squamous cell lung cancers
Sutherland et al. CancerCell 2011 — Cell of origin of small cell lung cancer inactivation of trp53 and rb1 in distinct cell types of adult mouse lung
Hanahan et al. Cell 2011 — Hallmarks of cancer the next generation
Mermel et al. GenomeBiol 2011 — GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in
Pao et al. LancetOncol 2011 — New driver mutations in non-small-cell lung cancer
DePristo et al. NatGenet 2011 — A framework for variation discovery and genotyping using next-generation DNA sequencing data
Chin et al. NatMed 2011 — Cancer genomics from discovery science to personalized medicine
Alkan et al. NatRevGenet 2011 — Genome structural variation discovery and genotyping
Bamshad et al. NatRevGenet 2011 — Exome sequencing as a tool for mendelian disease gene discovery
Navin et al. Nature 2011 — Tumour evolution inferred by single-cell sequencing
Sharma et al. Cell 2010 — A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations
Harris et al. NatRevClinOncol 2010 — The molecular pathology of cancer
Hawkins et al. NatRevGenet 2010 — Next-generation genomics an integrative approach
Metzker et al. NatRevGenet 2010 — Sequencing technologies-the next generation
Meyerson et al. NatRevGenet 2010 — Advances in understanding cancer genomes through second-generation sequencing
Filippakopoulos et al. Nature 2010 — Selective inhibition of BET bromodomains
Lee et al. Nature 2010 — The mutation spectrum revealed by paired genome sequences from a lung cancer patient
Pleasance et al. Nature 2010 — A comprehensive catalogue of somatic mutations from a human cancer genome
Vousden et al. Cell 2009 — Blinded by the light The growing complexity of p53
Brown et al. NatRevCancer 2009 — Awakening guardian angels drugging the p53 pathway
Segal et al. NatRevGenet 2009 — From DNA sequence to transcriptional behaviour a quantitative approach
Stratton et al. Nature 2009 — The cancer genome
Zhou et al. Nature 2009 — Novel mutant-selective EGFR kinase inhibitors against EGFR T790M
Karaman et al. NatBiotechnol 2008 — A quantitative analysis of kinase inhibitor selectivity
Bentley et al. Nature 2008 — Accurate whole human genome sequencing using reversible terminator chemistry
Ding et al. Nature 2008 — Somatic mutations affect key pathways in lung adenocarcinoma
TCGA et al. Nature 2008 — Comprehensive genomic characterization defines human glioblastoma genes and core pathways
Shibata et al. ProcNatlAcadSciUSA 2008 — Cancer related mutations in NRF2 impair its recognition by keap1-cul3 E3 ligase and promote malignancy
Yun et al. ProcNatlAcadSciUSA 2008 — The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP
Rikova et al. Cell 2007 — Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer
Christensen et al. MolCancerTher 2007 — Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-met, in
Zhang et al. Cell 2006 — An allosteric mechanism for activation of the kinase domain of epidermal growth factor receptor
Bryant et al. Nature 2005 — Specific killing of BRCA2-deficient tumours with inhibitors of poly(adp-ribose) polymerase
Farmer et al. Nature 2005 — Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy
International human genome sequencing consortium et al. Nature 2004 — Finishing the euchromatic sequence of the human genome
Schlessinger et al. Science 2004 — Common and distinct elements in cellular signaling via EGF and FGF receptors
Liang et al. NatRevCancer 2003 — Analysing differential gene expression in cancer
Chen et al. ClinCancerRes 2002 — Proteomic analysis of lung adenocarcinoma identification of a highly expressed set of proteins in tumors
Davies et al. Nature 2002 — Mutations of the BRAF gene in human cancer
Manning et al. Science 2002 — The protein kinase complement of the human genome
Weinstein et al. Science 2002 — Cancer. addiction to oncogenes-the achilles heal of cancer
Stein et al. NatRevGenet 2001 — Genome annotation from sequence to biology
Blume-Jensen et al. Nature 2001 — Oncogenic kinase signalling
Lander et al. Nature 2001 — Initial sequencing and analysis of the human genome
Cheung et al. Cell 2000 — Signaling to chromatin through histone modifications
Kornberg et al. Cell 1999 — Twenty-five years of the nucleosome, fundamental particle of the eukaryote chromosome

Basic-Others

Gan et al. AdvSci 2026 — Single-cell reveal GALNT7-dependent ferroptosis suppression as a mechanism of immunotherapy resistance in non-small
Osarogiagbon et al. AmSocClinOncolEducBook 2026 — Optimal use of targeted therapy and immunotherapy in early-stage, resectable non-small cell lung cancer
ODwyer et al. BMJOncol 2026 — Treatment of oligometastatic lung cancers new data, new drivers, new approaches
Enssle et al. CancerCell 2026 — Pathogenesis of diffuse large B cell lymphoma proteogenotypes
Liang et al. CancerCell 2026 — Spatial biomarker discovery via interpretable semantic learning in histopathology
Richter et al. CancerCell 2026 — A closed tumor-immune-brain circuit in cancer cachexia
Tang et al. CancerCell 2026 — Mapping cell type-resolved transcriptomic profiles to patient survival in pancreatic cancer
Xu et al. CancerCell 2026 — Received 24 february 2026
Zhang et al. CancerCell 2026 — Cancer cachexia a tumor-driven disorder of whole-body homeostasis
Marinello et al. CancerDiscov 2026 — Approaches in non-small cell lung cancer 2
Winslow et al. CancerDiscov 2026 — A roadmap to transform lung cancer outcomes priorities in biology, therapeutic innovation, early detection, prevention
Yiu et al. CancerDiscov 2026 — Same-slide spatial multiomics integration
Li et al. CancerImmunolRes 2026 — Peripheral th17 immune signature associates with excellent response to anti-PD1anti-PD-L1 therapy across solid tumors
Muneer et al. CancerLett 2026 — Deep learning of CT imaging predicts PD-L1 expression and immunotherapy response in metastatic NSCLC A multi-center
Zhu et al. CancerMed 2026 — Harnessing gut microbiota to enhance immunotherapy in NSCLC from mechanisms to translational applications
Clarke et al. CancerRes 2026 — Virtual tumors enable prediction of personalized therapeutic combinations for non-small cell lung cancer
Jiang et al. Cancers 2026 — Selective inhibition of KRASG13C reveals an increased dependence on wild-type RAS
Wang et al. Carcinogenesis 2026 — Camrelizumab, apatinib and radiotherapy in locally advanced, unresectable
Aggarwal et al. Cell 2026 — Engineered commensals for metabolic modulation of the gut-liver-brain axis
Conard et al. Cell 2026 — Tackling the complexity of cancer with generative models
Conrad et al. Cell 2026 — Cell death in cancer
Dohlman et al. Cell 2026 — Biodiversity and biogeography of the multi-kingdom cancer microbiome
Gao et al. Cell 2026 — Nanoparticles hijack calvarial immune cells for CNS drug delivery and stroke therapy
Hanahan et al. Cell 2026 — Hallmarks of cancer-then and now, and beyond
Hinterleitner et al. Cell 2026 — Senescence in cancer hallmarks, paradoxes, and therapeutic promise
Ho et al. Cell 2026 — Transposable element DNA and RNA drivers of gene expression, evolution, and disease
Li et al. Cell 2026 — Cellular architecture and neighborhood-informed virtual spatial tumor profiling from histopathology
Li et al. Cell 2026 — Multimodal clocks of human aging
Quail et al. Cell 2026 — Cancer ecosystems a dynamic interplay across scales
Song et al. Cell 2026 — Hijacking ERAD for targeted degradation of transmembrane proteins
Tzouanas et al. Cell 2026 — Hepatic adaptation to chronic metabolic stress primes tumorigenesis
Ueki et al. Cell 2026 — A CRISPR knockout mouse library for functional genomics in influenza research
Winkler et al. Cell 2026 — Cancer neuroscience the past, the present, and the road ahead
Xing et al. Cell 2026 — Deep-learning-based de novo discovery and design of therapeutics that reverse disease-associated transcriptional
deLaunoit et al. Cell 2026 — The spatiotemporal dynamics of postnatal vascularization in the mouse brain
Gao et al. CellMetab 2026 — The s100a8a9 complex promotes food intake and prevents adipose tissue loss during cancer cachexia in mice
Jia et al. CellMetab 2026 — Plasma proteomic signature of frailty in 50,506 adults
Liang et al. CellMetab 2026 — Large-scale metaproteomics of human gut microbiota reveals microbial functions in metabolic diseases and aging
Tiwari et al. CellRep 2026 — An orally active dual CBPp300 degrader targets core dependencies of multiple myeloma
Chae et al. ClinCancerRes 2026 — Mitochondrial imaging detects early cardiac changes following cancer immunotherapy
Repetto et al. ClinCancerRes 2026 — The genomic landscape of MYC, MYCL, and MYCN amplified solid tumors
Zhang et al. JAMA 2026 — An AI-based OCT system to detect diabetic macular edema
Strohbehn et al. JCOOncolPract 2026 — Maintenance PemetrexedPembrolizumab versus pembrolizumab in non-small cell lung cancer A propensity score-weighted
Morigny et al. JClinInvest 2026 — Inhibition of ceramide synthesis ameliorates body wasting in a cancer cachexia model
Rochelle et al. JClinInvest 2026 — Leveraging factors that control alveolar epithelial cell fate enables large-scale expansion for lung tissue engineering
Ruggero et al. JClinInvest 2026 — Rewriting the cancer proteome targeting selective translation as a
Oberstein et al. JClinOncol 2026 — Amivantamab monotherapy in chemorefractory RASBRAF wild-type metastatic colorectal cancer results from OrigAMI-1, an
Abascal et al. JImmunotherCancer 2026 — FLT3L-secreting cDC1 in situ vaccination enhances antitumor immunity and synergizes with PD-1 blockade in murine
Chen et al. JImmunotherCancer 2026 — Targeting CD74 may mitigate immune-escape features and enhance BCMA CAR-T activity in preclinical models of
Jong et al. JImmunotherCancer 2026 — Lenalidomide boosts CD1d-vdelta2 bispecific antibody-engaged Vgamma9Vdelta2-T cell effector functions via CD28, notch
Zhang et al. JImmunotherCancer 2026 — HDAC inhibitors reverse YAP-driven immune resistance in NSCLC mechanistic and translational evidence
Zhang et al. MolCell 2026 — PKCalpha-mediated nuclear translocation of cGAS stabilizes beta-catenin and drives metastasis
Zhu et al. MolCell 2026 — Mitochondrial glutamine import sustains electron transport chain integrity independently of glutaminolysis in cancer
Centre et al. NEnglJMed 2026 — Sodium bicarbonate for critically ill adults with metabolic acidosis and shock
Cohn et al. NEnglJMed 2026 — Lonvoguran ziclumeran-in vivo CRISPR gene editing in hereditary angioedema
Haber et al. NEnglJMed 2026 — Altering the diet to rewire cancer
OReilly et al. NEnglJMed 2026 — Daraxonrasib or chemotherapy in previously treated metastatic pancreatic cancer
Lu et al. NatAging 2026 — Proteomic signatures of the APOE epsilon4 and APOE epsilon2 genetic variants and alzheimer’s disease
Zhou et al. NatBiotechnol 2026 — Digital twins of ex vivo human lungs enable accurate and personalized evaluation of therapeutic efficacy
Frangieh et al. NatCancer 2026 — Single-cell and spatial profiling in cancer biology and clinical oncology
Gfeller et al. NatCancer 2026 — Advances in predicting t cell epitope recognition for cancer immunotherapy
Jimenez-Castano et al. NatCancer 2026 — Epithelial-to-mesenchymal transition as a central driver of tumor cell plasticity
Ge et al. NatCellBiol 2026 — Stress granules restrain ferroptosis by sequestering ferritin
Krey et al. NatCommun 2026 — The ISG atlas a loss-of-function analysis characterizes antiviral properties of interferon stimulated genes
Radke et al. NatCommun 2026 — RBM20 isoform regulation by independent transcription start sites adapts alternative splicing in development and disease
Cheruiyot et al. NatGenet 2026 — Inflammatory cytokines induce new cancer dependencies
Sarni et al. NatGenet 2026 — A progeria syndrome links DNA hypermethylation to age-related pathology
De et al. NatMed 2026 — Neoadjuvant stereotactic body radiation therapy with durvalumab and oleclumab in ER
Ding et al. NatMed 2026 — Plasma proteomic signatures of cellular aging predict human disease
Gentner et al. NatMed 2026 — Tumor-targeted interferon-alpha gene therapy for glioblastoma a phase 1 trial
Ke et al. NatMed 2026 — AI-induced never-skilling in medical education
Peng et al. NatMed 2026 — Savolitinib in MET-amplified gastric or gastroesophageal junction adenocarcinoma a phase 2 trial
Jiang et al. NatNanotechnol 2026 — Efficient prime editing in vivo and in vitro using lipid nanoparticles
Sanchez-Molina et al. NatNeurosci 2026 — Spatial proteomic analysis in human alzheimer’s disease brains enables identification of microenvironment-dependent
Zhu et al. NatProtoc 2026 — Differential protein expression analysis of quantitative mass spectrometry data using deqms
Rowles et al. NatRevCancer 2026 — Decoding cancer across scales with metabolomics
Saviano et al. NatRevCancer 2026 — Claudin proteins as emerging therapeutic targets for solid tumours
Pike et al. NatRevChem 2026 — Lessons learned in linking PROTACs from discovery to the clinic
Chen et al. NatRevClinOncol 2026 — Engineering platelets as cancer therapeutics
Kang et al. NatRevClinOncol 2026 — Translating ferroptosis into oncology challenges, opportunities and future directions
Guilbaud et al. NatRevDrugDiscov 2026 — Autophagy modulation in cancer
Monroe et al. NatRevDrugDiscov 2026 — Therapeutic targeting of neuroimmune mechanisms in neurodegeneration
Lee et al. NatRevImmunol 2026 — Glial cells in chronic inflammation diversity, dysfunction and therapeutic targeting
Turner et al. NatRevImmunol 2026 — RNA-binding proteins and ribonucleoproteins as determinants of immunity
Ehlers et al. NatRevNeurosci 2026 — Wired for immunity neuroimmune control of the lung by sensory neurons
Brixi et al. Nature 2026 — Genome modelling and design across all domains of life with evo 2
Davis et al. Nature 2026 — 25 years of chemistry that simply clicks
Gerhardt et al. Nature 2026 — Mutation-dependent responses to sleep and exercise in clonal haematopoiesis
Li et al. Nature 2026 — Spermine is an endogenous iron chelator that inhibits ferroptosis
Lu et al. Nature 2026 — Molecular glue degraders of HuR suppress BRAF-mutant colorectal cancer
Menendez-Montes et al. Nature 2026 — Mitochondria directly interact with the nuclear pore complex
Scholz et al. Nature 2026 — RNA-triggered cell killing with crispr-cas12a2
Yan et al. Nature 2026 — Ecotypes of triple-negative breast cancer in response to chemotherapy
Yue et al. Nature 2026 — Spatial distribution of the proteome in the human body and in cancers
Zeng et al. Nature 2026 — Human haematopoietic stem cells remember inflammatory stress
Zhang et al. Nature 2026 — The mutational landscape of STING-induced immunity
Lee et al. Neuron 2026 — Immune-brain plasticity underpins stress and affective behaviors
Liu et al. OncolRev 2026 — Progress in the application of 68ga-pentixafor petct in lung cancer a review
Dymun et al. SciTranslMed 2026 — Clinicogenomic analysis of
Western et al. SciTranslMed 2026 — Low overlap of plasma and CSF protein quantitative trait loci affects protein discovery for neurological disease
Kim et al. Science 2026 — Complex interplay of neuronal and hormonal gut-brain responses to essential amino acid deficit
Lin et al. Science 2026 — Antifibrotic drug finerenone restores fertility in premature ovarian insufficiency
Pearce et al. Science 2026 — Transcriptformer a generative cell atlas across 1.5 billion years of evolution
Davalos et al. TrendsCancer 2026 — How DNA methylation predicts response to cancer therapies
Janiak et al. TrendsCancer 2026 — Platelets the next-generation ovarian cancer biomarker
Conrad et al. Blood 2025 — Decoding functional hematopoietic progenitor cells in the adult human lung
Maltseva et al. MolOncol 2025 — Interplay of integrins and selectins in metastasis
DeMichele et al. NatMed 2025 — Targeting dormant tumor cells to prevent recurrent breast cancer a randomized phase 2 trial
Laisne et al. NatRevCancer 2025 — Epigenomic heterogeneity as a source of tumour evolution
Leunig et al. NatRevImmunol 2025 — Connection and communication between the nervous and immune systems
Hoover et al. Nature 2025 — Nerve-to-cancer transfer of mitochondria during cancer metastasis
Li et al. Nature 2025 — SPP1 is required for maintaining mesenchymal cell fate in pancreatic cancer
Li et al. ProcNatlAcadSciUSA 2025 — Targeting orthotopic and metastatic pancreatic cancer with allogeneic stem cell-engineered mesothelin-redirected
Liaki et al. ProcNatlAcadSciUSA 2025 — A targeted combination therapy achieves effective pancreatic cancer regression and prevents tumor resistance
Bojmar et al. NatMed 2024 — Multi-parametric atlas of the pre-metastatic liver for prediction of metastatic outcome in early-stage pancreatic cancer
Goto et al. Nature 2024 — SOX17 enables immune evasion of early colorectal adenomas and cancers
Chen et al. iScience 2024 — Translating CD47-targeted therapy in gastrointestinal cancers insights from preclinical to clinical studies
Falzone et al. Cell 2023 — Cancer chemotherapy
Finley et al. Cell 2023 — What is cancer metabolism
Horns et al. Cell 2023 — Engineering RNA export for measurement and manipulation of living cells
Shiraishi et al. Cell 2023 — Biophysical forces mediated by respiration maintain lung alveolar epithelial cell fate
Wang et al. CellDeathDiscov 2023 — Role of ADAM and ADAMTS proteases in pathological tissue remodeling
Tanaka et al. FEBSOpenBio 2023 — A mouse model of lung cancer induced via intranasal injection for anticancer drug screening and evaluation of pathology
Sharp et al. FrontImmunol 2023 — Experimental procedures for flow cytometry of wild-type mouse brain a systematic review
Aoki et al. InVivo 2023 — Precise and facile endotracheal lung-tumor-implantation mouse model visualized by GFP expression
Atkins et al. JClinOncol 2023 — Combination dabrafenib and trametinib versus combination nivolumab and ipilimumab for patients with advanced
Hadoux et al. NEnglJMed 2023 — Phase 3 trial of selpercatinib in advanced RET-mutant medullary thyroid cancer
Goswami et al. NatCancer 2023 — Myeloid-specific KDM6B inhibition sensitizes glioblastoma to PD1 blockade
Sikkema et al. NatMed 2023 — An integrated cell atlas of the lung in health and disease
Malfertheiner et al. NatRevDisPrimers 2023 — Helicobacter pylori infection
Zhang et al. ProcNatlAcadSciUSA 2023 — Integrin alpha5beta1 contributes to cell fusion and inflammation mediated by SARS-CoV-2 spike via RGD-independent
Pennitz et al. STARProtoc 2023 — Protocol to dissociate healthy and infected murine-and hamster-derived lung tissue for single-cell transcriptome anal…
Chen et al. BiomedPharmacother 2022 — Integrin-mediated cancer progression as a specific target in clinical therapy
Heazlewood et al. Blood 2022 — The RNA-binding protein SRSF3 has an essential role in megakaryocyte maturation and platelet production
Wen et al. Blood 2022 — Molecular mechanisms of leukocyte beta2 integrin activation
Newell et al. CancerCell 2022 — Multiomic profiling of checkpoint inhibitor-treated melanoma identifying predictors of response and resistance, and
Garciaz et al. CancerDiscov 2022 — Pharmacologic reduction of mitochondrial iron triggers a noncanonical BAXBAK-dependent cell death
Mirzalieva et al. Cells 2022 — ISG15 and ISGylation in human diseases
Kang et al. ExpMolMed 2022 — The diverse repertoire of ISG15 more intricate than initially thought
Rugo et al. JClinOncol 2022 — Sacituzumab govitecan in hormone receptor-PositiveHuman epidermal growth factor receptor 2-negative metastatic breast
Christian et al. MethodMolBiol 2022 — Cancer cell biology
Ferguson et al. NatCommun 2022 — The surfaceome of multiple myeloma cells suggests potential immunotherapeutic strategies and protein markers of drug
Mirhadi et al. NatCommun 2022 — Integrative analysis of non-small cell lung cancer patient-derived xenografts identifies distinct proteotypes
Song et al. NatCommun 2022 — Proteomic analysis reveals key differences between squamous cell carcinomas and adenocarcinomas across multiple tissues
LeSavage et al. NatMater 2022 — Next-generation cancer organoids
Nurk et al. Science 2022 — The complete sequence of a human genome
Hollox et al. TrendsGenet 2022 — Genome structural variation in human evolution
Zhu et al. CancerCell 2021 — Oncogenic extrachromosomal DNA functions as mobile enhancers to globally amplify chromosomal transcription
Hao et al. Cell 2021 — Integrated analysis of multimodal single-cell data
Schreiber et al. Cell 2021 — The rise of molecular glues
Flamini et al. CellDeathDis 2021 — Glucocorticoid-induced leucine zipper regulates liver fibrosis by suppressing CCL2-mediated leukocyte recruitment
Yang et al. CellRep 2021 — Dimensionality reduction by UMAP reinforces sample heterogeneity analysis in bulk transcriptomic data
Kay et al. CellsDev 2021 — Macropinocytosis biology and mechanisms
Wu et al. Innovation(Camb) 2021 — clusterProfiler 4.0 A universal enrichment tool for interpreting omics data
Martinez-Arroyo et al. IntJMolSci 2021 — Small rab GTPases in intracellular vesicle trafficking the case of Rab3ARaphillin-3a complex in the kidney
Borchers et al. JCellBiol 2021 — Who’s in control principles of rab GTPase activation in endolysosomal membrane trafficking and beyond
Kanemitsu et al. JClinOncol 2021 — Primary tumor resection plus chemotherapy versus chemotherapy alone for colorectal cancer patients with asymptomatic,
Winer et al. LancetOncol 2021 — Pembrolizumab versus investigator-choice chemotherapy for metastatic triple-negative breast cancer (KEYNOTE-119) a
Alvero et al. MethodMolBiol 2021 — Detection of cell death mechanisms
Cuklina et al. MolSystBiol 2021 — Diagnostics and correction of batch effects in large-scale proteomic studies a tutorial
Vancura et al. NARCancer 2021 — Cancer LncRNA census 2 (CLC2) an enhanced resource reveals clinical features of cancer lncRNAs
Burley et al. NEnglJMed 2021 — Predicting proteome-scale protein structure with artificial intelligence
Choueiri et al. NEnglJMed 2021 — Nivolumab plus cabozantinib versus sunitinib for advanced renal-cell carcinoma
Motzer et al. NEnglJMed 2021 — Lenvatinib plus pembrolizumab or everolimus for advanced renal cell carcinoma
Tanaka et al. NatCancer 2021 — Multi-omic profiling of peritoneal metastases in gastric cancer identifies molecular subtypes and therapeutic
Choi et al. NatCellBiol 2021 — Release of notch activity coordinated by IL-1beta signalling confers differentiation plasticity of airway progenitors
Rozeman et al. NatMed 2021 — Survival and biomarker analyses from the OpACIN-neo and OpACIN neoadjuvant immunotherapy trials in stage III melanoma
Rennick et al. NatNanotechnol 2021 — Key principles and methods for studying the endocytosis of biological and nanoparticle therapeutics
Rottenberg et al. NatRevCancer 2021 — The rediscovery of platinum-based cancer therapy
Koh et al. ProcNatlAcadSciUSA 2021 — A short ORF-encoded transcriptional regulator
Rosin et al. STARProtoc 2021 — Live-cell imaging of microglial interactions with radial glia in transgenic embryonic mouse brains using slice culture
Altae-Tran et al. Science 2021 — The widespread IS200IS605 transposon family encodes diverse programmable RNA-guided endonucleases
Ishiwata et al. TranslLungCancerRes 2021 — A preclinical research platform to evaluate photosensitizers for transbronchial localization and phototherapy of lung
Graw et al. ACSOmega 2020 — proteiNorm-A user-friendly tool for normalization and analysis of TMT and label-free protein quantification
Wilkinson et al. AnnuRevBiochem 2020 — RNA splicing by the spliceosome
Sinha et al. Biochemist 2020 — A beginner’s guide to mass spectrometry-based proteomics
Zhao et al. CancerCell 2020 — Large-scale characterization of drug responses of clinically relevant proteins in cancer cell lines
Nolan et al. CancerCellInt 2020 — Development of syngeneic murine cell lines for use in immunocompetent orthotopic lung cancer models
Dijkstra et al. CellRep 2020 — Challenges in establishing pure lung cancer organoids limit their utility for personalized medicine
Choi et al. CellStemCell 2020 — Inflammatory signals induce AT2 cell-derived damage-associated transient progenitors that mediate alveolar regeneration
Yao et al. CellStemCell 2020 — Patient-derived organoids predict chemoradiation responses of locally advanced rectal cancer
Miklavc et al. Cells 2020 — Actin and myosin in non-neuronal exocytosis
Schioppa et al. FrontCellDevBiol 2020 — Molecular basis for CCRL2 regulation of leukocyte migration
Lucotti et al. FrontOncol 2020 — Platelets and metastasis New implications of an old interplay
Calvo et al. IBRORep 2020 — Dissociation of neonatal and adult mice brain for simultaneous analysis of microglia, astrocytes and infiltrating
Kojima et al. JClinOncol 2020 — Randomized phase III KEYNOTE-181 study of pembrolizumab versus chemotherapy in advanced esophageal cancer
Ernst et al. JMedChem 2020 — Design of development candidate eFT226, a first in class inhibitor of eukaryotic initiation factor 4a RNA helicase
Elsallab et al. LancetOncol 2020 — CAR T-cell product performance in haematological malignancies before and after marketing authorisation
Powles et al. LancetOncol 2020 — Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma
Aguilan et al. MolOmics 2020 — Guide for protein fold change and p-value calculation for non-experts in proteomics
Alzahofi et al. NatCommun 2020 — Rab27a co-ordinates actin-dependent transport by controlling organelle-associated motors and track assembly proteins
Algazi et al. NatMed 2020 — Continuous versus intermittent BRAF and MEK inhibition in patients with BRAF-mutated melanoma a randomized phase 2 trial
Deng et al. NatMed 2020 — Characteristics of anti-CD19 CAR T cell infusion products associated with efficacy and toxicity in patients with large
Slyper et al. NatMed 2020 — A single-cell and single-nucleus RNA-Seq toolbox for fresh and frozen human tumors
Driehuis et al. NatProtoc 2020 — Establishment of patient-derived cancer organoids for drug-screening applications
Rohatgi et al. NatRevClinOncol 2020 — Cancer vaccine induces potent T cell responses-but is it enough
Konigs et al. NatStructMolBiol 2020 — SRSF7 maintains its homeostasis through the expression of split-ORFs and nuclear body assembly
Gilan et al. Science 2020 — Selective targeting of BD1 and BD2 of the BET proteins in cancer and immunoinflammation
Stuart et al. Cell 2019 — Comprehensive integration of single-cell data
Wagner et al. Cell 2019 — A single-cell atlas of the tumor and immune ecosystem of human breast cancer
Li et al. ClinCancerRes 2019 — The immune subtypes and landscape of squamous cell carcinoma
Yan et al. ColdSpringHarbPerspectBiol 2019 — Molecular mechanisms of pre-mRNA splicing through structural biology of the spliceosome
Hafemeister et al. GenomeBiol 2019 — Normalization and variance stabilization of single-cell RNA-seq data using regularized negative binomial regression
Xue et al. NatCommun 2019 — CDK46 inhibitors target SMARCA4-determined cyclin D1 deficiency in hypercalcemic small cell carcinoma of the ovary
Korsunsky et al. NatMethods 2019 — Fast, sensitive and accurate integration of single-cell data with harmony
Stuart et al. NatRevGenet 2019 — Integrative single-cell analysis
Chan et al. Nature 2019 — Molecular recording of mammalian embryogenesis
Tikhonova et al. Nature 2019 — The bone marrow microenvironment at single-cell resolution
Lee et al. Cell 2018 — Tumor evolution and drug response in patient-derived organoid models of bladder cancer
Stillman et al. Cell 2018 — Histone modifications insights into their influence on gene expression
Atkins et al. ClinCancerRes 2018 — Pembrolizumab plus pegylated interferon alfa-2b or ipilimumab for advanced melanoma or renal cell carcinoma
Maloney et al. ClinOrthopRelatRes 2018 — Intratibial injection causes direct pulmonary seeding of osteosarcoma cells and is not a spontaneous model of
Wolf et al. GenomeBiol 2018 — SCANPY large-scale single-cell gene expression data analysis
DiNardo et al. NEnglJMed 2018 — Durable remissions with ivosidenib in IDH1-mutated relapsed or refractory AML
Mejean et al. NEnglJMed 2018 — Sunitinib alone or nephrectomy for advanced RCC
Migden et al. NEnglJMed 2018 — PD-1 blockade with cemiplimab in advanced cutaneous squamous-cell carcinoma
Park et al. NEnglJMed 2018 — Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia
Butler et al. NatBiotechnol 2018 — Integrating single-cell transcriptomic data across different conditions, technologies, and species
Wang et al. NatMed 2018 — Metastatic cancers promote cachexia through ZIP14 upregulation in skeletal muscle
Hamidi et al. NatRevCancer 2018 — Every step of the way integrins in cancer progression and metastasis
Lytle et al. NatRevCancer 2018 — Stem cell fate in cancer growth, progression and therapy resistance
Ferguson et al. NatRevDrugDiscov 2018 — Kinase inhibitors the road ahead
McMahon et al. NatStructMolBiol 2018 — Yeast surface display platform for rapid discovery of conformationally selective nanobodies
La et al. Nature 2018 — RNA velocity of single cells
Sun et al. Nature 2018 — Genomic atlas of the human plasma proteome
Cohen et al. Science 2018 — Detection and localization of surgically resectable cancers with a multi-analyte blood test
Pereira et al. Science 2018 — Lymph node metastases can invade local blood vessels, exit the node, and colonize distant organs in mice
Izumchenko et al. AnnOncol 2017 — Patient-derived xenografts effectively capture responses to oncology therapy in a heterogeneous cohort of patients with
Lee et al. Cell 2017 — Anatomically and functionally distinct lung mesenchymal populations marked by Lgr5 and Lgr6
Lim et al. Cell 2017 — The principles of engineering immune cells to treat cancer
Kodack et al. CellRep 2017 — Primary patient-derived cancer cells and their potential for personalized cancer patient care
Johnson et al. CellRes 2017 — Driving gene-engineered T cell immunotherapy of cancer
Gupta et al. ClinCancerRes 2017 — Whole genomic copy number alterations in circulating tumor cells from men with abiraterone or enzalutamide-resistant
Chakravarty et al. JCOPrecisOncol 2017 — OncoKB A precision oncology knowledge base
Wolchok et al. NEnglJMed 2017 — Overall survival with combined nivolumab and ipilimumab in advanced melanoma
Zheng et al. NatCommun 2017 — Massively parallel digital transcriptional profiling of single cells
Batlle et al. NatMed 2017 — Cancer stem cells revisited
Cramer et al. NatMed 2017 — Systemic depletion of L-cyst(e)ine with cyst(e)inase increases reactive oxygen species and suppresses tumor growth
Furman et al. NatMed 2017 — Expression of specific inflammasome gene modules stratifies older individuals into two extreme clinical and
Aibar et al. NatMethods 2017 — SCENIC single-cell regulatory network inference and clustering
Lefrancais et al. Nature 2017 — The lung is a site of platelet biogenesis and a reservoir for haematopoietic progenitors
Ott et al. Nature 2017 — An immunogenic personal neoantigen vaccine for patients with melanoma
Bankhead et al. SciRep 2017 — QuPath open source software for digital pathology image analysis
Sinha et al. BioProtocol 2016 — Isolation of highly pure primary mouse alveolar epithelial type II cells by flow cytometric cell sorting
Kebriaei et al. JClinInvest 2016 — Phase I trials using sleeping beauty to generate CD19-specific CAR T cells
Ruella et al. JClinInvest 2016 — Dual CD19 and CD123 targeting prevents antigen-loss relapses after CD19-directed immunotherapies
Turtle et al. JClinInvest 2016 — CD19 CAR-T cells of defined CD4+-CD8+ composition in adult B cell ALL patients
Rosenberg et al. Lancet 2016 — Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following
Bray et al. NatBiotechnol 2016 — Near-optimal probabilistic RNA-seq quantification
Uhlen et al. NatMethods 2016 — A proposal for validation of antibodies
Broutier et al. NatProtoc 2016 — Culture and establishment of self-renewing human and mouse adult liver and pancreas 3d organoids and their genetic
OLeary et al. NatRevClinOncol 2016 — Treating cancer with selective CDK46 inhibitors
Goodwin et al. NatRevGenet 2016 — Coming of age ten years of next-generation sequencing technologies
Walsh et al. SciRep 2016 — Drug response in organoids generated from frozen primary tumor tissues
Wang et al. SciRep 2016 — THBS2 is a potential prognostic biomarker in colorectal cancer
Tirosh et al. Science 2016 — Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq
Ali et al. AnnOncol 2015 — PD-L1 protein expression in breast cancer is rare, enriched in basal-like tumours and associated with infiltrating
Anders et al. Bioinformatics 2015 — HTSeq-a python framework to work with high-throughput sequencing data
Davenport et al. CancerImmunolRes 2015 — CAR-T cells inflict sequential killing of multiple tumor target cells
Macosko et al. Cell 2015 — Highly parallel genome-wide expression profiling of individual cells using nanoliter droplets
Network et al. Cell 2015 — Genomic classification of cutaneous melanoma
Liberzon et al. CellSyst 2015 — The molecular signatures database (MSigDB) hallmark gene set collection
Casak et al. ClinCancerRes 2015 — FDA approval summary ramucirumab for gastric cancer
Lum et al. ClinCancerRes 2015 — Targeted T-cell therapy in stage IV breast cancer A phase I clinical trial
Chen et al. CurrBiol 2015 — Spliceosomes
Wang et al. DevCell 2015 — Formin-like 2 promotes beta1-integrin trafficking and invasive motility downstream of PKCalpha
Kundranda et al. DrugDesDevelTher 2015 — Albumin-bound paclitaxel in solid tumors clinical development and future directions
Pongor et al. GenomeMed 2015 — A genome-wide approach to link genotype to clinical outcome by utilizing next generation sequencing and gene chip data
Ahmed et al. JClinOncol 2015 — Human epidermal growth factor receptor 2 (HER2)-specific chimeric antigen receptor-modified T cells for the
Awad et al. JClinOncol 2015 — Durable responses with PD-1 inhibition in lung and kidney cancer and the ongoing search for predictive biomarkers
Cohen et al. JClinOncol 2015 — Controversies in the treatment of local and locally advanced gastric and esophageal cancers
Hamanishi et al. JClinOncol 2015 — Safety and antitumor activity of anti-PD-1 antibody, nivolumab, in patients with platinum-resistant ovarian cancer
Maio et al. JClinOncol 2015 — Five-year survival rates for treatment-naive patients with advanced melanoma who received ipilimumab plus dacarbazine
Park et al. JClinOncol 2015 — Efficacy and safety of CD19-targeted CAR-T for B-ALL
Schadendorf et al. JClinOncol 2015 — Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in unresectable or
Wang et al. JClinOncol 2015 — Immune therapy in GI malignancies A review
Ribas et al. LancetOncol 2015 — Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002) a randomised,
Pegram et al. Leukemia 2015 — IL-12-secreting CD19-targeted cord blood-derived T cells for the immunotherapy of B-cell acute lymphoblastic leukemia
Chapman et al. NEnglJMed 2015 — Rapid eradication of a bulky melanoma mass with one dose of immunotherapy
Motzer et al. NEnglJMed 2015 — Nivolumab versus everolimus in advanced renal-cell carcinoma
Postow et al. NEnglJMed 2015 — Nivolumab and ipilimumab versus ipilimumab in untreated melanoma
Robert et al. NEnglJMed 2015 — Nivolumab in previously untreated melanoma without BRAF mutation
Robert et al. NEnglJMed 2015 — Pembrolizumab versus ipilimumab in advanced melanoma
Satija et al. NatBiotechnol 2015 — Spatial reconstruction of single-cell gene expression data
Shukla et al. NatBiotechnol 2015 — Comprehensive analysis of cancer-associated somatic mutations in class I HLA genes
Cristescu et al. NatMed 2015 — Molecular analysis of gastric cancer identifies subtypes associated with distinct clinical outcomes
Gao et al. NatMed 2015 — High-throughput screening using patient-derived tumor xenografts to predict clinical trial drug response
Long et al. NatMed 2015 — 4-1bb costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors
Newman et al. NatMethods 2015 — Robust enumeration of cell subsets from tissue expression profiles
Bachireddy et al. NatRevCancer 2015 — Haematological malignancies at the forefront of immunotherapeutic innovation
Bertotti et al. Nature 2015 — The genomic landscape of response to EGFR blockade in colorectal cancer
DeLosAngeles et al. Nature 2015 — Hallmarks of pluripotency
Spranger et al. Nature 2015 — Melanoma-intrinsic beta-catenin signalling prevents anti-tumour immunity
Ritchie et al. NucleicAcidsRes 2015 — Limma powers differential expression analyses for RNA-sequencing and microarray studies
Madore et al. PigmentCellMelanomaRes 2015 — PD-L1 expression in melanoma shows marked heterogeneity within and between patients implications for anti-PD-1pd-L1
Garrett et al. Science 2015 — Cancer and the microbiota
Rosenberg et al. Science 2015 — Adoptive cell transfer as personalized immunotherapy for human cancer
Wu et al. Science 2015 — Remote control of therapeutic T cells through a small molecule-gated chimeric receptor
Zhang et al. AmJTranslRes 2014 — Comparative membrane proteomic analysis between lung adenocarcinoma and normal tissue by iTRAQ labeling mass
Nakajima et al. AnnThoracSurg 2014 — Orthotopic lung cancer murine model by nonoperative transbronchial approach
Bolger et al. Bioinformatics 2014 — Trimmomatic a flexible trimmer for illumina sequence data
Liao et al. Bioinformatics 2014 — featureCounts an efficient general purpose program for assigning sequence reads to genomic features
Sun et al. BreastCancerRes 2014 — Construction and evaluation of a novel humanized HER2-specific chimeric receptor
Doi et al. CancerChemotherPharmacol 2014 — Phase I dose-escalation study of the HSP90 inhibitor AUY922 in japanese patients with advanced solid tumors
Wang et al. CancerImmunolRes 2014 — Targeting fibroblast activation protein in tumor stroma with chimeric antigen receptor T cells can inhibit tumor growth
Gao et al. Cell 2014 — Organoid cultures derived from patients with advanced prostate cancer
Lee et al. Cell 2014 — Lung stem cell differentiation in mice directed by endothelial cells via a BMP4-NFATc1-thrombospondin-1 axis
Heiss et al. ClinCancerRes 2014 — The role of relative lymphocyte count as a biomarker for the effect of catumaxomab on survival in malignant ascites
Ahmed et al. FEBSLett 2014 — Engineering anti-GD2 monoclonal antibodies for cancer immunotherapy
Love et al. GenomeBiol 2014 — Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2
Watanabe et al. IntJOncol 2014 — A stem cell medium containing neural stimulating factor induces a pancreatic cancer stem-like cell-enriched population
Barrington et al. JClinOncol 2014 — Role of imaging in the staging and response assessment of lymphoma consensus of the international conference on
Topalian et al. JClinOncol 2014 — Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab
Yamanaka et al. ModRheumatol 2014 — Estimates of the prevalence of and current treatment practices for rheumatoid arthritis in japan using reimbursement
Weaver et al. MolBiolCell 2014 — How taxolpaclitaxel kills cancer cells
Trapnell et al. NatBiotechnol 2014 — The dynamics and regulators of cell fate decisions are revealed by pseudotemporal ordering of single cells
Zheng et al. NatMed 2014 — Anchored multiplex PCR for targeted next-generation sequencing
Cancer et al. Nature 2014 — Comprehensive molecular characterization of gastric adenocarcinoma
Pellegrini et al. Oncologist 2014 — Prognostic value of interim positron emission tomography in patients with peripheral T-cell lymphoma
Hanzelmann et al. BMCBioinformatics 2013 — GSVA gene set variation analysis for microarray and RNA-seq data
Dobin et al. Bioinformatics 2013 — STAR ultrafast universal RNA-seq aligner
Rivera et al. Cell 2013 — Mapping human epigenomes
Barlan et al. CurrOpinCellBiol 2013 — The journey of the organelle teamwork and regulation in intracellular transport
Tirino et al. FASEBJ 2013 — Cancer stem cells in solid tumors an overview and new approaches for their isolation and characterization
Iglesias-Ussel et al. JImmunolMethods 2013 — Isolation of microarray-quality RNA from primary human cells after intracellular immunostaining and
Hamid et al. NEnglJMed 2013 — Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma
Wolchok et al. NEnglJMed 2013 — Nivolumab plus ipilimumab in advanced melanoma
Frampton et al. NatBiotechnol 2013 — Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing
Themeli et al. NatBiotechnol 2013 — Generation of tumor-targeted human T lymphocytes from induced pluripotent stem cells for cancer therapy
Alexandrov et al. Nature 2013 — Signatures of mutational processes in human cancer
Gao et al. SciSignal 2013 — Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal
Vogelstein et al. Science 2013 — Cancer genome landscapes
Saunders et al. Bioinformatics 2012 — Strelka accurate somatic small-variant calling from sequenced tumor-normal sample pairs
Cerami et al. CancerDiscov 2012 — The cBio cancer genomics portal an open platform for exploring multidimensional cancer genomics data
Glickman et al. Cell 2012 — Converting cancer therapies into cures lessons from infectious diseases
Nik-Zainal et al. Cell 2012 — Mutational processes molding the genomes of 21 breast cancers
Weickhardt et al. JThoracOncol 2012 — Local ablative therapy of oligoprogressive disease prolongs disease control by tyrosine kinase inhibitors in
Cheng et al. MolBiolCell 2012 — Myosin 1e coordinates actin assembly and cargo trafficking during clathrin-mediated endocytosis
Topalian et al. NEnglJMed 2012 — Safety, activity, and immune correlates of anti-PD-1 antibody in cancer
Langmead et al. NatMethods 2012 — Fast gapped-read alignment with Bowtie 2
Schindelin et al. NatMethods 2012 — Fiji an open-source platform for biological-image analysis
Barretina et al. Nature 2012 — The cancer cell line encyclopedia enables predictive modelling of anticancer drug sensitivity
ENCODE et al. Nature 2012 — An integrated encyclopedia of DNA elements in the human genome
Network et al. Nature 2012 — Comprehensive molecular characterization of human colon and rectal cancer
Network et al. Nature 2012 — Comprehensive molecular portraits of human breast tumours
Bustos et al. ProcNatlAcadSciUSA 2012 — Rab27 and rab3 sequentially regulate human sperm dense-core granule exocytosis
Scholler et al. SciTranslMed 2012 — Decade-long safety and function of retroviral-modified chimeric antigen receptor T cells
Cahu et al. AnnOncol 2011 — 18f-fluorodeoxyglucose-positron emission tomography before, during and after treatment in mature TNK lymphomas a study
Li et al. BMCBioinformatics 2011 — RSEM accurate transcript quantification from RNA-seq data with or without a reference genome
Savoldo et al. JClinInvest 2011 — CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients
Robbins et al. JClinOncol 2011 — Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered
Chen et al. JNatlCancerInst 2011 — Concurrent chemoradiotherapy vs radiotherapy alone in stage II nasopharyngeal carcinoma phase III randomized trial
Opitz-Araya et al. JVisExp 2011 — Organotypic hippocampal slice cultures
Chapman et al. NEnglJMed 2011 — Improved survival with vemurafenib in melanoma with BRAF V600E mutation
Robert et al. NEnglJMed 2011 — Ipilimumab plus dacarbazine for previously untreated metastatic melanoma
Robinson et al. NatBiotechnol 2011 — Integrative genomics viewer
Martin et al. NatRevGenet 2011 — Next-generation transcriptome assembly
Network et al. Nature 2011 — Integrated genomic analyses of ovarian carcinoma
Quinlan et al. Bioinformatics 2010 — BEDTools a flexible suite of utilities for comparing genomic features
Robinson et al. Bioinformatics 2010 — edgeR a bioconductor package for differential expression analysis of digital gene expression data
Wilkerson et al. Bioinformatics 2010 — ConsensusClusterPlus a class discovery tool with confidence assessments and item tracking
Jena et al. Blood 2010 — Redirecting T-cell specificity by introducing a tumor-specific chimeric antigen receptor
Madsen et al. DevCell 2010 — Cancer dissemination-lessons from leukocytes
Morrisey et al. DevCell 2010 — Preparing for the first breath genetic and cellular mechanisms in lung development
Chen et al. FEBSJ 2010 — Comparison of membrane fraction proteomic profiles of normal and cancerous human colorectal tissues with gel-assisted
Weiler-Sagie et al. JNuclMed 2010 — (18)f-FDG avidity in lymphoma readdressed a study of 766 patients
Hodi et al. NEnglJMed 2010 — Improved survival with ipilimumab in patients with metastatic melanoma
Wang et al. NucleicAcidsRes 2010 — ANNOVAR functional annotation of genetic variants from high-throughput sequencing data
Li et al. Bioinformatics 2009 — Fast and accurate short read alignment with burrows-wheeler transform
Li et al. Bioinformatics 2009 — The sequence AlignmentMap format and SAMtools
Sugahara et al. CancerCell 2009 — Tissue-penetrating delivery of compounds and nanoparticles into tumors
DiGiacomo et al. CancerImmunolImmunother 2009 — Therapeutic efficacy of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with metastatic melanoma
Okamoto et al. CancerRes 2009 — Improved expression and reactivity of transduced tumor-specific TCRs in human lymphocytes by specific silencing of
Yvon et al. ClinCancerRes 2009 — Immunotherapy of metastatic melanoma using genetically engineered GD2-specific T cells
Langmead et al. GenomeBiol 2009 — Ultrafast and memory-efficient alignment of short DNA sequences to the human genome
Pio et al. JThoracOncol 2009 — Alternative splicing in lung cancer
JVisExp 2009 — Adenocarcinoma engraftment A method to implant cancer cells into the murine lungs
DuPage et al. NatProtoc 2009 — Conditional mouse lung cancer models using adenoviral or lentiviral delivery of cre recombinase
Huang et al. NatProtoc 2009 — Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources
Carpenito et al. ProcNatlAcadSciUSA 2009 — Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137
Karanikas et al. CancerBiolTher 2008 — Co-expression patterns of tumor-associated antigen genes by non-small cell lung carcinomas implications for
Arai et al. CurrBiol 2008 — Ypt11 functions in bud-directed transport of the golgi by linking myo2 to the coatomer subunit ret2
Zhang et al. GenomeBiol 2008 — Model-based analysis of ChIP-Seq (MACS)
vanMeer et al. NatRevMolCellBiol 2008 — Membrane lipids where they are and how they behave
Wherry et al. Immunity 2007 — Molecular signature of CD8 T cell exhaustion during chronic viral infection
Roland et al. MolBiolCell 2007 — Myosin vb interacts with rab8a on a tubular network containing EHD1 and EHD3
Johannessen et al. CellMolLifeSci 2006 — The multifunctional roles of the four-and-a-half-LIM only protein FHL2
Lamers et al. JClinOncol 2006 — Treatment of metastatic renal cell carcinoma with autologous T-lymphocytes genetically retargeted against carbonic
Roeder et al. NatMed 2006 — Dynamic modeling of imatinib-treated chronic myeloid leukemia functional insights and clinical implications
Lee et al. ProcNatlAcadSciUSA 2006 — Evolution and expression of chimeric POTE-actin genes in the human genome
Rowinsky et al. SeminOncol 2006 — Novel agents that target tublin and related elements
Hoepfner et al. Cell 2005 — Modulation of receptor recycling and degradation by the endosomal kinesin KIF16B
Michor et al. Nature 2005 — Dynamics of chronic myeloid leukaemia
Subramanian et al. ProcNatlAcadSciUSA 2005 — Gene set enrichment analysis a knowledge-based approach for interpreting genome-wide expression profiles
Bera et al. Gene 2004 — Five POTE paralogs and their splice variants are expressed in human prostate and encode proteins of different lengths
Ferrara et al. NatRevDrugDiscov 2004 — Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer
Ibrahim et al. ClinCancerRes 2002 — Phase I and pharmacokinetic study of ABI-007, a cremophor-free, protein-stabilized, nanoparticle formulation of
Dudley et al. Science 2002 — Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes
Jordens et al. CurrBiol 2001 — The rab7 effector protein RILP controls lysosomal transport by inducing the recruitment of dynein-dynactin motors
Fontijn et al. MolCellBiol 2001 — The human kinesin-like protein RB6K is under tight cell cycle control and is essential for cytokinesis
Venter et al. Science 2001 — The sequence of the human genome
Hanahan et al. Cell 2000 — The hallmarks of cancer
Herrmann et al. CurrOpinCellBiol 2000 — Intermediate filaments and their associates multi-talented structural elements specifying cytoarchitecture and
Doki et al. BrJCancer 1999 — Mediastinal lymph node metastasis model by orthotopic intrapulmonary implantation of Lewis lung carcinoma cells in mice
Hirata et al. ClinCancerRes 1999 — Pharmacokinetic study of S-1, a novel oral fluorouracil antitumor drug
Chapman et al. JClinOncol 1999 — Phase III multicenter randomized trial of the dartmouth regimen versus dacarbazine in patients with metastatic melanoma
Al et al. JClinOncol 1998 — Sarraf-Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer phase III randomized int…
Horwich et al. JClinOncol 1997 — Randomized trial of bleomycin, etoposide, and cisplatin compared with bleomycin, etoposide, and carboplatin in
Cortes et al. JClinOncol 1995 — Docetaxel
Hwu et al. JExpMed 1993 — Lysis of ovarian cancer cells by human lymphocytes redirected with a chimeric gene composed of an antibody variable
Jodrell et al. JClinOncol 1992 — Relationships between carboplatin exposure and tumor response and toxicity in patients with ovarian cancer
Motzer et al. JClinOncol 1987 — Residual mass an indication for further therapy in patients with advanced seminoma following systemic chemotherapy
Harding et al. JCellBiol 1983 — Receptor-mediated endocytosis of transferrin and recycling of the transferrin receptor in rat reticulocytes

Research Wiki

エクスプローラー

lung-cancer-biology